BiotechTube
Vizgen

Vizgen

Cambridge, United States· Est.
vizgen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $83.2M

Overview

Vizgen is a private, commercial-stage biotechnology company pioneering the spatial multi-omics field with its MERSCOPE and InSituPlex platforms. The company's core technology, MERFISH 2.0, allows for the in-situ mapping of up to 1,000 RNA targets at single-cell resolution across large tissue areas, including FFPE samples. With over 200 MERSCOPE platforms installed globally and a recent $48M financing round, Vizgen is positioned for growth as it expands its commercial footprint and advances its integrated spatial biology solutions. The company serves researchers in oncology, neuroscience, and immunology, aiming to accelerate therapeutic discovery and diagnostics.

OncologyNeuroscienceImmunology

Technology Platform

Integrated spatial multi-omics platforms featuring MERFISH 2.0 for high-plex, single-cell spatial transcriptomics (MERSCOPE Platform) and InSituPlex for multiplex spatial proteomics, supported by STARVUE AI analytics.

Funding History

2
Total raised:$83.2M
Series B$69.2M
Series A$14M

Opportunities

The spatial biology market is experiencing rapid growth, driven by demand for tools that connect molecular data to tissue context in drug discovery and diagnostics.
Vizgen's integrated multi-omics approach and large installed base position it to capture significant market share and expand into clinical applications.

Risk Factors

Intense competition from established and emerging spatial biology companies poses a constant threat to market position.
Successful commercial execution and the transition to profitability are critical, as is navigating the complexity of a technology that requires significant user expertise for broad adoption.

Competitive Landscape

Vizgen competes in the high-plex spatial transcriptomics segment against companies like 10x Genomics (Xenium) and NanoString (CosMx), and in spatial proteomics against Akoya Biosciences. Its differentiation lies in the high single-cell resolution and large gene plex of MERFISH 2.0 and its integrated multi-omics strategy.

More companies in United States →